

Clinical research and operations professional with extensive experience in the biotech and pharmaceutical industry. Skilled in Good Clinical Practice (GCP), global clinical trial management (Phase I-IV), and clinical operations oversight. Proficient in program management, consistently achieving study milestones within budget and timelines through effective collaboration within the CRO and Pharmaceutical/Biotechnology model. Notable achievements include contributing to two successful NDA submissions, resulting in the introduction of new drugs for Type 2 Diabetes and Major Depressive Disorder. Led the Phase 3 team to obtain Emergency Use Approval for mRNA-1273, a COVID-19 vaccine.